Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Xtandi

This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer. The evaluation is based on positive results from the PROSPER trial. ... Erleada is the first to claim approval, but Xtandi benefits from longstanding familiarity in CRPC treatment.

Latest news

More from news
Approximately 28 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

  • Deal Watch May 2016 Deal Watch May 2016

    The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already

  • Deal Watch March 2016 Deal Watch March 2016

    Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

  • Astellas: Ten years young Astellas: Ten years young

    Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess

  • Pharma deals in February 2015 Pharma deals in February 2015

    Challenges associated with turning this asset around e.g. complex production, sky-high price tag, looming competition from oral rivals Xtandi (Astellas) and Medivation) and Zytiga (J&J) will be daunting.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Astellas makes senior EMEA appointments Astellas makes senior EMEA appointments

    Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.

  • Astellas poaches new oncology head from Takeda Astellas poaches new oncology head from Takeda

    She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The heart of the matter: Part One

    Proof of this can be seen in NICE’ s recent reversal of its negative decision on the cancer drug Xtandi, where England’ s health technology assessment (HTA) body was swayed by

  • The heart of the matter: Part One

    Proof of this can be seen in NICE’ s recent reversal of its negative decision on the cancer drug Xtandi, where England’ s health technology assessment (HTA) body was swayed by

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia